Last updated on February 2018

High-Dose Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs


Brief description of study

the purpose of this study is to evaluate the efficacy and safety of high-dosepulsatile Erlotinib/Gefitinib in advanced non small cell lung cancer (NSCLC) patients after failure of standard dose EGFR-TKIsEpidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Detailed Study Description

To evaluate the efficacy and safety by treating the advanced non small cell lung cancer (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)

Clinical Study Identifier: NCT01965275

Contact Investigators or Research Sites near you

Start Over

Yueyin Pan, MD

Dept. of Oncology,The First Affiliated Hospital of Anhui Medical Univesrsity
Hefei, China
  Connect »